Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
miRagen Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'miRagen Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the miRagen Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of miRagen Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of miRagen Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of miRagen Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the miRagen Therapeutics, Inc.'s pipeline products Reasons to buy - Evaluate miRagen Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of miRagen Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the miRagen Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of miRagen Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of miRagen Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of miRagen Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 miRagen Therapeutics, Inc. Snapshot 5 miRagen Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 miRagen Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 miRagen Therapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 miRagen Therapeutics, Inc. - Pipeline Products Glance 11 miRagen Therapeutics, Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 miRagen Therapeutics, Inc. - Drug Profiles 13 MGN-1374 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 MGN-4220 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 MGN-4893 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 MGN-5804 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 MGN-6114 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 MGN-8107 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 MGN-9103 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Oligonucleotide for Cardiometabolic Diseases 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 RNAi Oligonucleotide to Inhibit miR-145 for PAH 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Antisense Oligonucleotide for Cardivascular Disease 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 miRagen Therapeutics, Inc. - Pipeline Analysis 23 miRagen Therapeutics, Inc. - Pipeline Products by Target 23 miRagen Therapeutics, Inc. - Pipeline Products by Molecule Type 24 miRagen Therapeutics, Inc. - Pipeline Products by Mechanism of Action 25 miRagen Therapeutics, Inc. - Recent Pipeline Updates 26 miRagen Therapeutics, Inc. - Dormant Projects 28 miRagen Therapeutics, Inc. - Locations And Subsidiaries 29 Head Office 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables miRagen Therapeutics, Inc., Key Information 5 miRagen Therapeutics, Inc., Key Facts 5 miRagen Therapeutics, Inc. - Pipeline by Indication, 2014 8 miRagen Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9 miRagen Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10 miRagen Therapeutics, Inc. - Preclinical, 2014 11 miRagen Therapeutics, Inc. - Discovery, 2014 12 miRagen Therapeutics, Inc. - Pipeline by Target, 2014 23 miRagen Therapeutics, Inc. - Pipeline by Molecule Type, 2014 24 miRagen Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 25 miRagen Therapeutics, Inc. - Recent Pipeline Updates, 2014 26 miRagen Therapeutics, Inc. - Dormant Developmental Projects,2014 28
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.